Product Overview
CJC-1295 (No DAC) / Ipamorelin is a dual-compound growth hormone secretagogue blend. It is supplied as a lyophilized material in multiple selectable formulations for lawful laboratory, analytical, and non-clinical research.
Included Compounds
- CJC-1295 (No DAC) — Modified GRF (1–29)
- Ipamorelin
Research Context
CJC-1295 (No DAC), more accurately described as Modified GRF (1–29), is a 29-amino acid analog of growth hormone-releasing hormone (GHRH). Material sold under the “CJC-1295 (No DAC)” designation lacks the Drug Affinity Complex (DAC) moiety present in the original CJC-1295 formulation, resulting in a shorter physiological half-life and different pharmacokinetic behavior. Researchers should account for this distinction when interpreting data from publications that examine DAC-containing variants. Ipamorelin is a synthetic pentapeptide growth hormone secretagogue (GHS) that acts on the ghrelin receptor to stimulate endogenous growth hormone release. The combination of a GHRH analog and a GHS represents a research strategy to target dual pathways of growth hormone secretion.
Research References
- CJC-1295-Related Research References (Note: Some citations examine DAC-containing CJC-1295, which exhibits a significantly extended half-life compared to the No DAC variant. Findings related to DAC-containing formulations should not be assumed to be equivalent to the No DAC material.)
- Teichman SL, et al. “Prolonged pharmacokinetics and pharmacodynamics of CJC-1295, a long-acting growth hormone-releasing hormone analogue.” Journal of Clinical Endocrinology and Metabolism. 2006;91(3):795–801. DOI: 10.1210/jc.2005-1536.
- Teichman SL, et al. “Safety and tolerability of a drug affinity complex growth hormone-releasing hormone analogue in healthy subjects.” Journal of Clinical Endocrinology and Metabolism. 2006;91(7):2602–2608. DOI: 10.1210/jc.2005-2533.
